 |
|
|
| |
FIB -4 and FibroScan Can Identify Patients With Nonalcoholic Fatty Liver Disease Who Are at Risk of Liver-Related Events: Results of a Longitudinal Analysis With Comparison With Liver Biopsy
|
| |
| |
AASLD 2020 Nov 11-16
Jerome Boursier1; Hannes Hagstrom2; mattias eksted3t; ClemenCe moreau4; martin BonaCCi5; sandrine Cure5; aldo trylesinski5; manuel romero-gomez6
1Angers University Hospital, Angers, France; 2Karolinska University Hospital, Stockholm, Sweden; 3Department of Health, Medicine and Caring Sciences, Linkoping University, Linkoping, Sweden; 4Laboratoire HIFIH, Angers University, Angers, France; 5Intercept Pharmaceuticals, London, UK; 6Virgen del Rocio University Hospital and University of Seville, Sevilla, Spain
Disclosures: Jerome Boursier: Board membership, consulting, grant/research finding, speaking, and teaching for Intercept Pharmaceuticals, Inc.; speaking and teaching for Siemens, Echosens, and Eli Lily; board membership, speaking, and teaching for Gilead. Hannes Hagstrom: Board advisory for Bristol-Myers Squibb and Gilead and research grants to his institution from AstraZeneca, Gilead, and Intercept Pharmaceuticals, Inc. Mattias Ekstedt: Board advisor for AMRA Medical and research grants to his institution from AstraZeneca, Gilead, and Intercept Pharmaceuticals, Inc. Clemence Moreau: Employed by Angers University. Martin Bonacci, Sandrine Cure, and Aldo Trylesinski: Employed by Intercept Pharmaceuticals, Inc.. Manuel Romero-Gomez: None
|
| |
|
|
|
|
|
